Earnings Call Insights: ACADIA Pharmaceuticals Inc. (ACAD) Q1 2025
Management View
- CEO Catherine Owen Adams highlighted a strong start to 2025 with quarterly revenues of $244.3 million, a year-over-year increase of 19%. She emphasized growth in both DAYBUE and NUPLAZID sales and reiterated